Filing Flows › Hims & Hers Health (HIMS) › Guidance history
Hims & Hers Health (HIMS) guidance history: what it guided and what it reported
Hims & Hers Health gave guidance in 11 earnings releases on file since Feb 26, 2024. Of 9 guided periods since reported, it met or beat its own guidance 9 times (100%). Revenue: 9 of 9, on average +3.1% against the guided midpoint. Its releases raised guidance 7 times and lowered it 0 times.
Revenue
Met or beat 9 of 9 periods (5 above, 4 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q3 2026 | $880M–$900M (Aug 10, 2026) | — | to be reported | — |
| Q2 2026 | $680M–$700M (May 11, 2026) | $753M | above the range | +9.2% |
| Q1 2026 | $600M–$625M (Feb 23, 2026) | $608M | within the range | -0.7% |
| FY2026 | $2.7B–$2.9B (Feb 23, 2026) → raised $2.8B–$3.0B (May 11, 2026) → raised $3.1B–$3.3B (Aug 10, 2026) | — | to be reported | — |
| Q4 2025 | $605M–$625M (Nov 3, 2025) | $618M | within the range | +0.5% |
| FY2025 | $2.3B–$2.4B (Feb 24, 2025) → reaffirmed $2.3B–$2.4B (May 5, 2025) → reaffirmed $2.3B–$2.4B (Aug 4, 2025) → lowered $2.3B–$2.4B (Nov 3, 2025) | $2.3B | within the range | +0.1% |
| Q3 2025 | $570M–$590M (Aug 4, 2025) | $599M | above the range | +3.3% |
| Q2 2025 | $530M–$550M (May 5, 2025) | $545M | within the range | +0.9% |
| Q1 2025 | $520M–$540M (Feb 24, 2025) | $586M | above the range | +10.6% |
| Q4 2024 | $465M–$470M (Nov 4, 2024) | $481M | above the range | +2.9% |
Adjusted revenue
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.3B (Aug 10, 2026) | — | to be reported | — |
| FY2025 | $1.3B (May 5, 2025) | — | — | — |
| FY2030 | $1.3B (May 5, 2025) → reaffirmed $1.3B (Feb 23, 2026) → reaffirmed $1.3B (May 11, 2026) | — | to be reported | — |
Operating cash flow
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2030 | $6.5B (Feb 23, 2026) | — | to be reported | — |
Adjusted EBITDA
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q3 2026 | $75.0M–$95.0M (Aug 10, 2026) | — | to be reported | — |
| Q2 2026 | $35.0M–$55.0M (May 11, 2026) | — | — | — |
| FY2026 | $300M–$375M (Feb 23, 2026) → lowered $275M–$350M (May 11, 2026) → lowered $275M–$325M (Aug 10, 2026) | — | to be reported | — |
| Q1 2026 | $300M–$375M (Feb 23, 2026) | — | — | — |
| Q4 2025 | $55.0M–$65.0M (Nov 3, 2025) | — | — | — |
| Q3 2025 | $60.0M–$70.0M (Aug 4, 2025) | — | — | — |
| FY2030 | $1.3B (May 5, 2025) | — | to be reported | — |
| Q2 2025 | $65.0M–$75.0M (May 5, 2025) | — | — | — |
| FY2025 | $270M–$320M (Feb 24, 2025) → raised $295M–$335M (May 5, 2025) → reaffirmed $295M–$335M (Aug 4, 2025) → lowered $307M–$317M (Nov 3, 2025) | — | — | — |
| Q1 2025 | $270M–$320M (Feb 24, 2025) | — | — | — |
Adjusted EBITDA margin
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q3 2026 | 9.0%–11.0% (Aug 10, 2026) | — | to be reported | — |
| Q2 2026 | 5.0%–8.0% (May 11, 2026) | — | — | — |
| FY2026 | 11.0%–13.0% (Feb 23, 2026) → lowered 10.0%–12.0% (May 11, 2026) → lowered 9.0%–10.0% (Aug 10, 2026) | — | to be reported | — |
| Q1 2026 | 6.0%–9.0% (Feb 23, 2026) | — | — | — |
| Q4 2025 | 9.0%–10.0% (Nov 3, 2025) | — | — | — |
| Q3 2025 | 11.0%–12.0% (Aug 4, 2025) | — | — | — |
| Q2 2025 | 12.0%–14.0% (May 5, 2025) | — | — | — |
| FY2025 | 12.0%–13.0% (Feb 24, 2025) → raised 13.0%–14.0% (May 5, 2025) → reaffirmed 13.0%–14.0% (Aug 4, 2025) → lowered 13.0% (Nov 3, 2025) | — | — | — |
| Q1 2025 | 11.0%–12.0% (Feb 24, 2025) | — | — | — |
| Q4 2024 | 11.0%–12.0% (Nov 4, 2024) | — | — | — |
The latest quarter
Hims & Hers Health, Q2 2026: revenue $753M (+38% year over year), operating margin -12.9%, net loss $86.3M, operating cash flow −$35.9M. The chart follows the revenue to costs, profit and cash.
Questions
Does Hims & Hers Health beat its guidance?
Hims & Hers Health gave guidance in 11 earnings releases on file since Feb 26, 2024. Of 9 guided periods since reported, it met or beat its own guidance 9 times (100%). Revenue: 9 of 9, on average +3.1% against the guided midpoint.
How often does Hims & Hers Health raise guidance?
Its earnings releases raised guidance 7 times and lowered it 0 times since Feb 26, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.